---
title: 'Clinical Daily Summary: What Happened on November 16, 2026'
headline: Amylyx reports 55% fewer hypoglycemic events with avexitide in Phase 3
description: CG Oncology reported lower bladder-cancer recurrence risk, while Helus’s
  depression result came with safety questions.
url: https://thebench.bio/news/clinical/2026-11-16
topic: clinical
date: '2026-11-16'
covers:
- '2026-11-16'
date_published: '2026-11-16T12:02:05Z'
date_modified: '2026-11-17T00:02:26Z'
tags:
- Clinical
- Industry
- Research
sources: 9
publisher: TheBench.Bio
---

# Clinical Daily Summary: What Happened on November 16, 2026

**Amylyx reports 55% fewer hypoglycemic events with avexitide in Phase 3**

CG Oncology reported lower bladder-cancer recurrence risk, while Helus’s depression result came with safety questions.

## Today in brief

Amylyx said avexitide cut the combined rate of confirmed moderate and severe hypoglycemic events by 55% versus placebo in a 78-person Phase 3 trial. [1] In a separate 367-person Phase 3 study, CG Oncology reported a 68% lower bladder-tumor recurrence risk with cretostimogene than with no post-surgery treatment. [2] [3]

Helus said its psychedelic candidate reduced depression scores more than placebo at six and 12 weeks, but several serious adverse events raised safety concerns. [4]

## Avexitide reduced hypoglycemic events in a Phase 3 trial

Amylyx’s investigational drug avexitide cut the combined weekly rate of confirmed Level 2 and adjudicated Level 3 hypoglycemic events by 55% versus placebo during the 16-week blinded phase. [1] The least-squares mean rate was 0.55 events per week with avexitide and 1.24 with placebo, a statistically significant difference. [1]

The randomized study enrolled 78 adults whose hypoglycemia developed after Roux-en-Y gastric bypass surgery. [1] It also met secondary event-rate endpoints, including reductions of 63% in Level 2 events and 47% in Level 3 events. [1]

Reported side effects were mainly mild-to-moderate gastrointestinal or injection-site problems. There were no treatment-related serious adverse events or deaths. [1] The FDA had granted avexitide a designation for post-bariatric hypoglycemia. [1]

## Cretostimogene cut bladder-cancer recurrence risk by 68%

CG Oncology reported that cretostimogene was associated with a 68% lower recurrence risk than the control arm in the Phase 3 PIVOT-006 study. [2] [3] The trial enrolled 367 people with intermediate-risk or high-grade Ta non-muscle-invasive bladder cancer after complete tumor removal. Median follow-up was 17 months. [3]

The control group received no intervention after surgery. [3] Cretostimogene is an engineered common cold virus delivered into the bladder through a catheter. [2]

The study reported no treatment-related adverse events of Grade 3 or higher and no treatment-related discontinuations. [3] CG Oncology said it expects to submit an expanded biologics license application for these patient groups in the second quarter of 2027. [3]

## Helus reports depression benefit alongside serious adverse events

Helus Pharma said its psychedelic candidate improved depression symptoms in a Phase 3 trial when added to participants’ usual antidepressants. [4] At six weeks, scores on the Montgomery–Åsberg Depression Rating Scale fell by 19.5 points in the treatment group and 11.9 points with placebo. [4]

At 12 weeks, scores fell by 16.9 points with the drug and 9.9 points with placebo. The between-group differences were statistically significant at both time points. [4] Most of the treatment-group improvement was sustained through week 12. [4]

The study had several serious adverse events, prompting questions about safety. [4]

## Also worth knowing

- A post hoc analysis of the 3,417-person REDEFINE 1 trial found that 67.8% of CagriSema recipients had lost at least 5% of their starting weight by week eight. Early responders had greater average weight loss by week 68 than delayed responders, 25.4% versus 17.8%. [5]
- Aclaris Therapeutics’ bosakitug missed the primary and secondary endpoints in its Phase 2 atopic dermatitis trial. The company reported target engagement and said the drug was generally well tolerated. [6]
- PlaqueTec’s BIOPATTERN trial recruited its 100th participant and is operating at eight NHS cardiac centers, with a target of 300 participants by 2027. [7]
- Ossium Health’s initial 12-patient study of deceased-donor bone marrow transplants is fully enrolled. The company says its product can reach transplant centers in as little as 31 hours, compared with a usual 12-to-15-week timeline. [8]
- A survey of 354 prescreening respondents found that users of AI voice screening were more likely than web-form users to schedule and attend appointments. Because participants self-selected their screening method, the association does not establish causation. [9]

## The day in numbers

- **55%**: Reduction versus placebo in the combined rate of confirmed Level 2 and Level 3 hypoglycemic events with avexitide. [1]
- **68%**: Lower bladder-cancer recurrence risk reported with cretostimogene versus the control arm. [2] [3]
- **19.5 vs. 11.9 points**: Depression-score reductions at six weeks with Helus’s candidate and placebo, respectively. [4]

## Also published

- [Novo says Wegovy shot works in childhood obesity](<https://pharmaphorum.com/news/novo-says-wegovy-shot-works-childhood-obesity>), pharmaphorum
- [Helus shares slide on psychedelic readout in depression](<https://pharmaphorum.com/news/helus-shares-slide-psychedelic-readout-depression>), pharmaphorum
- [Geopolitical shifts in trial outsourcing](<https://european-biotechnology.com/sponsored-publications/geopolitical-shifts-in-trial-outsourcing/>), European Biotechnology
- [TL1A antibodies: a new inflammatory disease market ](<https://www.labiotech.eu/in-depth/tl1a-antibodies/>), Labiotech
- [ACT Brief: Screening Inconsistencies in Oncology, FDA Voucher Pilot Pause, and Patient AI Use](<https://www.appliedclinicaltrialsonline.com/view/screening-inconsistencies-oncology-fda-voucher-pilot-pause-patient-ai-use>), Applied Clinical Trials
- [Mastering Latin America's Supply Chains to Unlock a Clinical Trials Hotspot](<https://www.fiercepharma.com/resource/mastering-latin-americas-supply-chains-unlock-clinical-trials-hotspot>), Fierce Pharma

## Sources

1. [Amylyx reveals data from Phase III LUCIDITY trial of avexitide](<https://www.clinicaltrialsarena.com/news/amylyxs-avexitide-meets-primary-endpoint-lucidity-trial/>), Clinical Trials Arena, 2026-11-16
2. [STAT+: Bladder cancer immunotherapy from CG Oncology reduced risk of tumor recurrence](<https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/?utm_campaign=rss>), STAT Biotech, 2026-11-16
3. [CG Oncology’s stock up as gene therapy gains second win in NMIBC](<https://www.clinicaltrialsarena.com/news/cg-oncologys-stock-up-as-gene-therapy-gains-second-win-in-nmibc/>), Clinical Trials Arena, 2026-11-16
4. [STAT+: Helus’ psychedelic drug improved depression in study but faces safety questions](<https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss>), STAT Biotech, 2026-11-16
5. [Novo reports positive Phase III REDEFINE 1 results for CagriSema](<https://www.clinicaltrialsarena.com/news/novo-positive-redefine-1-results-cagrisema/>), Clinical Trials Arena, 2026-11-16
6. [Aclaris Therapeutics’ mAb fails in Phase II eczema trial](<https://www.clinicaltrialsarena.com/news/aclaris-therapeutics-mab-fails-in-phase-ii-eczema-trial/>), Clinical Trials Arena, 2026-11-16
7. [PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres](<https://pharmafile.com/news/plaquetec-coronary-disease-trial-reaches-100-patients-across-eight-nhs-centres/>), Pharmafile, 2026-11-16
8. [The Ron Lanton Report: Ossium Health's Bone Marrow Bank](<https://www.biopharminternational.com/view/ron-lanton-report-ossium-healths-bone-marrow-bank>), BioPharm International, 2026-11-16
9. [Participant Experience with AI-Assisted and Web-Based Clinical Trial Pre-Screening](<https://www.appliedclinicaltrialsonline.com/view/participant-experience-ai-assisted-web-based-clinical-trial-pre-screening>), Applied Clinical Trials, 2026-11-16

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.clinicaltrialsarena.com/news/amylyxs-avexitide-meets-primary-endpoint-lucidity-trial/>
[2]: <https://www.statnews.com/2026/11/16/bladder-cancer-immunotherapy-reduced-tumor-recurrence-cg-oncology/?utm_campaign=rss>
[3]: <https://www.clinicaltrialsarena.com/news/cg-oncologys-stock-up-as-gene-therapy-gains-second-win-in-nmibc/>
[4]: <https://www.statnews.com/2026/11/16/helus-psychedelics-depression-phase-3-trial/?utm_campaign=rss>
[5]: <https://www.clinicaltrialsarena.com/news/novo-positive-redefine-1-results-cagrisema/>
[6]: <https://www.clinicaltrialsarena.com/news/aclaris-therapeutics-mab-fails-in-phase-ii-eczema-trial/>
[7]: <https://pharmafile.com/news/plaquetec-coronary-disease-trial-reaches-100-patients-across-eight-nhs-centres/>
[8]: <https://www.biopharminternational.com/view/ron-lanton-report-ossium-healths-bone-marrow-bank>
[9]: <https://www.appliedclinicaltrialsonline.com/view/participant-experience-ai-assisted-web-based-clinical-trial-pre-screening>
